Related by context. All words. (Click for frequent words.) 76 Bayer HealthCare Onyx Pharmaceuticals 71 oral picoplatin 70 Tarvacin Anti Cancer 70 albiglutide currently 69 hematological tumors 67 novel tubulin binding 67 IIa trials 66 Aplidin 66 evaluating mipomersen 66 PRESEPT study 66 deCODE ProstateCancer TM 65 3 registrational trial 65 hematological indications 65 PI3K/Akt pathway inhibitor 65 vaccine GMK 65 kidney urologic 65 IIa clinical trials 65 tubulin inhibitor 65 castration resistant hormone refractory 65 novel therapeutic antibodies 65 haematological cancers 65 AKT inhibitor 64 recurrent metastatic 64 GVAX ® 64 alvespimycin 64 Quinamed 64 CYT# potent vascular disrupting 64 Zemplar Capsules 64 ARRY # 64 oral PTH 64 IIa trial 64 taxane refractory 64 refractory metastatic 64 relapsed MM 64 Phase Ib II 64 dimebon latrepirdine 63 TOCOSOL Camptothecin 63 Archexin 63 sapacitabine CYC# 63 metastatic colorectal 63 CG# oncolytic virus 63 tumor malignancies 63 VEGFR2 inhibitor 63 BrachySil TM 63 TELINTRA R 63 BRIM2 63 farletuzumab 63 PF # [002] 63 refractory colorectal cancer 63 novel antimitotic agent 63 NEUVENGE 63 DCVax R 63 tramiprosate Alzhemed TM 63 R#/MEM # 63 Phase 1b clinical trials 63 IMC #B 63 LungAlert TM 63 lung pancreatic 62 anti PlGF 62 TransVax ™ 62 HCD# [002] 62 Crofelemer budesonide foam 62 IMA# 62 ASONEP TM 62 TNFerade TM 62 Phase #b/#a clinical 62 samalizumab 62 ® bortezomib 62 acyclovir Lauriad R 62 LymphoStat B belimumab 62 next generation URAT1 62 LymphoStat B TM 62 Deforolimus 62 Aeolus Pharmaceuticals Announces 62 Telatinib 62 dose escalation Phase 62 ospemifene 62 MDS AML 62 treating sarcoma testicular 62 SUCCEED trial 62 rALLy clinical trial 62 phase Ib 62 metastatic renal 62 progressive metastatic prostate 62 XL# SAR# 62 rALLy 62 metastatic bladder 62 squamous non 62 motesanib 62 CINQUIL 62 selective angiogenic kinase inhibitor 62 clinical trials Archexin 62 Panzem R NCD 62 paclitaxel poliglumex 62 benign prostatic hyperplasia enlarged 62 CRLX# 62 bladder ovarian 62 demonstrated antitumor activity 62 metastatic pancreatic 61 CCR9 antagonist 61 5 fluorouracil leucovorin 61 KRAS mutated 61 AVN# Phase 61 Evoltra ® 61 BioSante LibiGel Phase III 61 initiate multicenter 61 hepatocellular carcinoma liver 61 EndoTAGTM 1 61 phase IIb study 61 MEK inhibitor RDEA# 61 LHRH receptor positive 61 GLP toxicology studies 61 HDL Selective Delipidation 61 novel nucleoside analog 61 Chronic myeloid leukemia 61 forodesine 61 systemic anaplastic large 61 Avastin adjuvant 61 Nicole Onetto MD 61 lymphomas leukemias 61 recurrent metastatic ovarian cancer 61 pancreatic colon 61 LBH# 61 Acute myelogenous leukemia 61 BRAF mutant 61 HuMax EGFr 61 Colon polyps 61 intra arterial chemotherapy 61 Stage IIB 61 pediatric malignancies 61 biliary tract cancer 61 human IgG1 monoclonal 61 budesonide foam 61 HGS# 61 Capesaris 61 CBLC# 61 Hormone Refractory Prostate Cancer 61 PSMA ADC 61 MKC# MT 61 Annamycin 61 deCODE AF TM 61 BRIM3 61 TNFerade ™ 61 adhesion molecule EpCAM expressing 61 PANVAC VF 61 volociximab 61 trastuzumab DM1 T DM1 61 Panzem ® 61 plus dacarbazine 61 nucleoside tide 61 hematologic tumors 61 TTR amyloidosis 61 compound INCB# 61 Curaxin CBLC# 60 HQK 60 gastro intestinal inflammation 60 Phase lll 60 Inhaled nitric oxide 60 SUTENT ® 60 IMPACT DCM 60 Oncosphere System 60 Dose escalation 60 inhaled AAT 60 Vicinium TM 60 PLX STROKE targeting 60 doublet chemotherapy 60 IIa Clinical Trial 60 immunotherapeutic approaches 60 imetelstat GRN#L 60 multicenter dose escalation 60 Elagolix 60 pain palliation 60 ONCONASE R 60 NPC 1C 60 colorectal ovarian 60 oral prodrug 60 mGluR2 NAM 60 Troxatyl 60 IMPDH inhibitor 60 OMP #R# 60 solid tumors ZYBRESTAT 60 BRCA deficient 60 JAK inhibitors 60 novel chimeric natriuretic 60 TBC# 60 pediatric acute lymphoblastic 60 Motesanib 60 JunJing II 60 TEMSO 60 Vitaxin 60 oncolytic virus therapies 60 IIa clinical 60 Quinamed R 60 Hepatocellular Carcinoma HCC 60 recombinant PSMA vaccine 60 retinal vein occlusion induced 60 evaluating Nexavar 60 DAC HYP 60 endometrial breast 60 surgically resectable 60 pharmacogenomic translational research 60 telomerase inhibitor drug 60 Novolimus 60 Phase 1a clinical 60 maximally tolerated dose 60 leukemia multiple myeloma 60 Alessandro Riva 60 therapeutic monoclonal antibody 60 targeted radiotherapeutic 60 nucleotide analog 60 deforolimus 60 Virulizin ® 60 Prednisone Against Refractory 60 lintuzumab SGN 60 mertansine 60 Insegia 60 AML acute myeloid 60 patient derived xenografts 60 essential thrombocythemia ET 60 follicular Non Hodgkin 60 PROSTVAC VF 60 accumulate preferentially 60 Phase 2b clinical trials 60 drug Treanda 60 Syncria albiglutide 60 MEND CABG II 60 Allovectin 7 60 cause mesothelioma asbestosis 60 assessing T DM1 60 immuno therapeutic 60 anticoagulant reversing agent 60 drug figitumumab 60 drug NP2 Enkephalin 60 potent suppressor 60 Vascugel ® 59 TKM PLK1 59 confirmatory pivotal 59 colorectal bladder 59 metastatic androgen independent 59 receiving chemoradiation therapy 59 Immunotherapeutic 59 include VALSTAR TM 59 Omacetaxine 59 Solazed 59 non nucleoside inhibitor 59 Harry Palmin President 59 immunotherapeutic vaccine 59 targeting miR 59 Achieves Primary Endpoint 59 HEPLISAV TM hepatitis B 59 evaluating tivozanib 59 Bioaccelerate compounds under 59 HGS ETR2 59 Thiarabine 59 elderly myelodysplastic syndromes 59 generation URAT1 inhibitor 59 evaluating satraplatin 59 Antisoma AS# 59 metastatic renal cell 59 ThermoDox R 59 Phase #/#a trial 59 Aflibercept 59 OHR/AVR# 59 receptor tyrosine kinase inhibitor 59 previously untreated follicular 59 papillary renal cell carcinoma 59 Panzem R 59 aurora kinase inhibitor 59 isoform selective 59 Tykerb lapatinib 59 TransVax 59 metaglidasen 59 nonsmall cell lung cancer 59 evaluating picoplatin 59 Trastuzumab DM1 59 treatmentof 59 thetreatment 59 multicenter Phase II 59 Empatic ™ 59 candidates Azedra TM 59 GRN# 59 YONDELIS 59 MAGE A3 ASCI 59 Lixivaptan 59 metastatic liver 59 initiate Phase 2b 59 XL# anticancer compounds 59 Liposomal Grb 2 59 fusion enhancers 59 hematologic cancers 59 SinuNase ™ 59 candidate TNFerade biologic 59 HGS ETR1 mapatumumab 59 ovarian endometrial 59 selectively inhibit replication 59 corticosteroid dexamethasone 59 Phase 2a clinical trials 59 AE# vaccine 59 refractory chronic lymphocytic 59 paclitaxel Taxol ® 59 CTAP# Capsules 59 ALB # 59 trial evaluating PRX# 59 cardiac perfusion 59 optimal dosing regimens 59 PRESEPT 59 pancreatic prostate 59 commercialize deforolimus 59 novel histone deacetylase 59 developed preclinically 59 gastrointestinal stromal 59 myeloproliferative neoplasms MPNs 59 molecular imaging radiopharmaceuticals 59 Squalamine 59 PEGylated interferon 59 humanized therapeutic 59 CDAD Clostridium difficile 59 Combination REOLYSIN R 59 including eniluracil ADH 59 omacetaxine mepesuccinate 59 refractory Hodgkin 59 Bezielle 59 resistant hormone refractory 59 enzastaurin 59 Litx 59 rhabdoid 59 azilsartan medoxomil 59 cervical prostate 59 ALN VSP Phase 59 antibody MAb 59 evaluating T DM1 59 Phase #b/#a 59 dasatinib Sprycel 59 multi kinase inhibitor 59 oral talactoferrin 59 OvaRex R 59 recurrent glioblastoma 59 TBC M4 59 HIV coinfected 59 Alzhemed TM 59 inflammation metabolic disorders 59 Canvaxin TM 59 ACAPODENE 59 Qnexa TM 59 INTEGRILIN R eptifibatide Injection 59 CholeraGarde R 59 candidate CRLX# 59 Glufosfamide 59 Proellex TM 59 brivanib 59 LUX Lung 58 palifosfamide Zymafos TM 58 TRAIL receptor antibodies 58 AFREZZA TM 58 Exherin TM 58 albiglutide 58 docetaxel Taxotere R 58 Budesonide foam crofelemer 58 INCB# [001] 58 IV RSD# 58 ELACYT 58 EGFR mutation positive 58 ZFP Therapeutics 58 oral deforolimus 58 ACAPODENE TM 58 GVAX Pancreas Vaccine 58 Xanafide 58 evaluate ZFP Therapeutic 58 OvaRex 58 TTF Therapy 58 PTK# 58 neratinib 58 AMPK activators 58 ovarian pancreatic 58 GVAX R 58 preclinical efficacy 58 NP2 Enkephalin 58 Darinaparsin 58 GALNS 58 Scopus Affiliation Identifier 58 CCX# 58 midstage clinical 58 relapsed refractory AML 58 EP #R 58 advanced medullary thyroid 58 Curaxin 58 FOLFOX6 chemotherapy regimen 58 include ColorectAlert TM 58 advanced metastatic prostate 58 IIb clinical trial 58 Myocet 58 Provectus Pharmaceuticals specializes 58 inhibit metastasis 58 Dose Escalation 58 BRAF mutated 58 Trofex 58 drug GAP #B# 58 octreotide implant 58 dyslipidemia hypertension diabetes 58 aflibercept VEGF Trap 58 CytoFab ™ 58 Ostabolin C TM 58 Personalized Immunotherapy 58 BR.# 58 Amgen Neulasta R 58 melanoma ovarian 58 Novo TTF 58 Azedra 58 Phase 1b 58 vidofludimus 58 Biopharmaceuticals AG 58 mg/m2 cohort 58 Crohn colitis 58 monoclonal antibody conjugated 58 Daclizumab 58 chronic thromboembolic pulmonary 58 BRAF inhibitor 58 MKC# 58 PrevOnco ™ 58 recurrent malignant glioma 58 JAK3 inhibitor 58 PresbyLens ® 58 Phase Ib IIa 58 galiximab 58 bapineuzumab AAB 58 serine protease inhibitor CU# 58 Amgen Neulasta ® 58 ThermoDox ® clinical 58 PEG SN# 58 MKC# MKC# PP 58 HuLuc# 58 RNAi therapeutic platform 58 Tesmilifene 58 TRIOLEX HE# 58 lung cancer NSCLC 58 Peginterferon alfa 2b 58 incyclinide 58 AN# novel 58 Recurrent Chest Wall 58 ALN HTT 58 immune modulating 58 GENASIS 58 basal cell carcinoma squamous 58 riociguat 58 novel peptide therapeutics 58 Phase IIb clinical trials 58 Genasense oblimersen sodium Injection 58 HRPC ovarian cancer 58 ChronVac C R 58 Tectin TM 58 Bioral Amphotericin B 58 PNP inhibitor 58 rxRNA 58 evaluating Actimmune 58 IIa clinical trial 58 metastatic gastric 58 generation purine nucleoside 58 CLL SLL 58 davalintide 58 regorafenib 58 Phase Ib clinical 58 novel immunotherapies 58 HuMax CD#b 58 personalized cellular immunotherapy 58 targeted radiotherapeutics 58 Myriad Flurizan 58 T1c 58 SPRYCEL ® 58 Hedgehog antagonist 58 treating peripheral arterial 58 pralatrexate injection folate analogue 58 sunitinib malate 58 R sorafenib tablets 58 Inc. Nasdaq NLTX 58 lymphoma multiple myeloma 58 Panzem 58 phase IIa 58 recurrent glioma 58 MCSP respectively 58 Ceplene/IL-2 58 Albuferon Phase 58 Phase IIA 58 p# inhibitor 58 Prodarsan R 58 plus octreotide LAR 58 pharmacokinetic PK study 58 romazarit 58 NSABP C 58 Exelixis compounds 58 catheter occlusion 58 Ophena TM 58 KSP inhibitor 58 rindopepimut 58 immunotherapeutic agent 58 nilotinib Tasigna ® 58 ATRA IV 58 Sudhir Agrawal D.Phil 58 Oncotype 58 THR beta agonist 58 initiated Phase Ib 58 confirmatory clinical 58 telomerase therapeutic 58 LAB CGRP 58 Adnectin 58 Pimavanserin 58 PLK1 SNALP 58 Panzem NCD 58 ZACTIMA 58 CCR5 mAb 57 SYMMETRY SM trial 57 omega interferon 57 Cloretazine ® 57 dose intramuscular 57 Mipomersen 57 MediGene focuses 57 IMiDs ® 57 Acetavance TM intravenous acetaminophen 57 generation rotary VAD 57 Syncria R 57 Adjuvant Treatment 57 interferon alpha IFN 57 Kahalalide F 57 VELCADE novel 57 relapsed mantle 57 Afatinib 57 successfully commercialize Iluvien 57 im peramivir 57 M# rationally 57 Phase III ADT 57 SNT MC# 57 VersaFilm 57 Vaxfectin R formulated 57 ® lenalidomide 57 torezolid phosphate 57 IDI MRSA 57 CMV vaccine 57 CAPACITY trials 57 indolent follicular non 57 Genz # 57 APEX PD 57 MGN# 57 CAMPATH 57 endothelin antagonist 57 polycythemia vera essential thrombocythemia 57 Hsp# Inhibitor 57 Tarceva TM 57 Pertuzumab 57 rotavirus shingles 57 BrachySil ™ 57 INSPIRE Trial Phase III 57 Antibody Drug Conjugate 57 zileuton injection 57 CD# CEA 57 cardio metabolic diseases 57 NS5B polymerase 57 dosing cohort 57 cellular immunotherapy 57 differentiated thyroid 57 aldehyde dehydrogenase ALDH2 deficiency 57 epithelial tumors 57 FUSILEV enhances 57 oral ridaforolimus 57 Aplidin R 57 ovarian prostate 57 neurogenic orthostatic hypotension NOH 57 metastatic malignant 57 LibiGel ® testosterone gel 57 adrenergic regulation 57 OvaRex ® MAb 57 completely resected 57 colon pancreatic 57 Phase 2a trial 57 vivo preclinical 57 HGS ETR1 57 Oncogenex 57 Lenocta 57 velafermin 57 ALK inhibitors 57 P#X# antagonist 57 Initiates Enrollment 57 ara C 57 GED aPC 57 Vicriviroc 57 Benlysta belimumab 57 antiretroviral naïve 57 endocrine refractory 57 recurrent glioblastoma multiforme GBM 57 EDEMA3 trial 57 Temsirolimus 57 OncoVEX GM CSF 57 molecular imaging pharmaceuticals 57 PRECISE Trial 57 ulimorelin 57 MEK inhibitors 57 trastuzumab DM1 57 Apoptone 57 neovascular diseases 57 Begins Dosing 57 carbohydrate polymers 57 Anavex #-# 57 HER2 amplified 57 registrational trial 57 refractory cutaneous T 57 Occlusin TM 57 Solazed TM 57 evaluating Prochymal 57 OnDose TM 57 adecatumumab MT# 57 osteolytic bone disease 57 treat secondary hyperparathyroidism 57 taxane chemotherapy administered 57 neoadjuvant treatment 57 agonistic human 57 oral sapacitabine 57 sarcoma melanoma 57 Surfaxin LS 57 induced macular edema 57 Advaxis Phase 57 ® natalizumab 57 recombinant biopharmaceutical 57 MET inhibitor 57 Zalypsis 57 Her2 positive 57 non nucleoside HCV 57 CML CP 57 recurrent ovarian 57 anti HGF antibody 57 ORACLE MS 57 Rezular 57 chronic myeloid 57 Aquinox 57 RNAi therapeutic targeting PCSK9 57 Lucanix R 57 humanised antibody 57 Telik logo TELINTRA 57 novel VDA molecule 57 Neuvenge 57 Viprinex TM 57 lenalidomide Revlimid R 57 lymphoid malignancies 57 gefitinib Iressa 57 Initiates Phase II 57 TransVax TM 57 recurrent NSCLC 57 BrachySil 57 severe oral mucositis 57 ACTEMRA TM 57 TroVax ® 57 CHAMPION PCI 57 Nanobody R 57 Testosterone MDTS R 57 NADiA 57 mTOR inhibition 57 ATL# [001] 57 indibulin 57 SNS# T 57 Denufosol 57 Gastrointestinal Stromal Tumors 57 humanised monoclonal antibody 57 trodusquemine 57 apricitabine ATC 57 Completes Patient Enrollment 57 haematologic 57 hormone receptor negative 57 DPX Survivac 57 MGd 57 PhG alpha 1 57 AAG geldanamycin analog 57 recurrent epithelial ovarian 57 proprietary radiolabeled monoclonal 57 carcinoma HCC 57 Phase Ib study 57 Ophena 57 systemic RNAi therapeutic 57 NOX E# 57 BRAF V#E mutation 57 Diamyd r 57 include Ischemic Paraplegia 57 Tramiprosate ALZHEMED TM 57 figitumumab 57 gamma secretase inhibitor 57 novel oral anticoagulant 57 concurrent chemoradiation 57 Cimzia TM 57 ANAVEX #-# [001] 57 novel L DOS# 57 NO# [002] 57 ErbB2 positive 57 pertuzumab 57 triggers apoptosis programmed 57 sorafenib Nexavar ® 57 TKB# 57 NABTT 57 histologic subtype 57 radiation chemoradiation 57 medically inoperable 57 Chronic lymphocytic leukemia CLL 56 EMPOWER TM 56 Initiate Clinical Trial 56 ficlatuzumab 56 Ribavirin causes 56 HER2 positive metastatic breast 56 AVAX AC Vaccine 56 polycythemia vera PV 56 REG2 56 reduce serum phosphate 56 DDP# 56 EndoTAG TM 56 metastatic colorectal carcinoma 56 initiate Phase IIb 56 Testosterone MDTS ® 56 Factor VIIa 56 Triapine 56 squamous cell lung cancer 56 investigational therapies 56 haematologic malignancies 56 nalbuphine ER 56 Hedgehog Pathway Inhibitor 56 PROLARIS 56 budesonide MMX Phase III 56 demonstrated clinically meaningful 56 immatics 56 motesanib diphosphate 56 Fodosine 56 Shigatoxin producing E. coli 56 thrombin inhibiting aptamer 56 PDE4 inhibitor 56 treatment naive genotype 56 Xcytrin R 56 pan histone deacetylase 56 Dural Sealant 56 oral ghrelin agonist 56 enhance ApoA 56 Elestrin ® 56 Submits Response 56 colorectal lung 56 edifoligide E2F Decoy 56 initiate Phase IIa 56 vaccines oncolytic virus 56 INxin 56 Huaiyin Power Plant 56 selective S#P# receptor agonist 56 Enzastaurin 56 IMiDs R 56 Successfully Completes Phase 56 ADVANCE ILLUMINATE 56 phase IIa clinical 56 cardiac revascularization 56 TransVax tm 56 damage cirrhosis liver 56 pediatric neuroblastoma 56 DIFICID ™ 56 huN# DM1 56 oxidative stress inducer 56 TRAIL R1 56 leading oral taxane 56 Estrogen receptor positive 56 Xelox 56 ORAL Solo 56 RCW breast cancer 56 de novo kidney transplant 56 Lilly Alimta 56 cardiovascular disease osteoporosis 56 CTA# Injection 56 anaplastic astrocytoma AA 56 Initiates Clinical 56 Alferon N 56 Zybrestat 56 cediranib 56 PEG PAL 56 oral RELISTOR 56 CVac 56 PRT# 56 Activity Assay 56 Albuferon albinterferon alfa 2b 56 Hedgehog inhibitor 56 refractory indolent non 56 neuropathic pain spasticity 56 biologic therapeutics 56 antiangiogenesis therapies 56 pediatric pontine glioma 56 COSIRA trial 56 Initiates Clinical Trial 56 REGEN trial 56 investigational HCV polymerase 56 ragweed allergy immunotherapeutic 56 MEND CABG 56 novel radiopharmaceuticals 56 brain metastases originating 56 Aurora kinase inhibitor 56 BLA filing 56 paclitaxel Taxol R 56 prognostic biomarkers 56 Rigel R# 56 acetonide FA 56 Alocrest 56 iSONEP ™ 56 Sapacitabine 56 EMPOWER Study 56 ProSavin 56 Amigal TM 56 Platinol ® cisplatin 56 IAP inhibitor 56 oral mTOR inhibitor 56 tolevamer 56 antiangiogenic agent 56 Darusentan 56 PROVENGE ® 56 treats acute lymphoblastic 56 hormonally sensitive 56 SPEAR Study 56 RhuDex R 56 Cloretazine R VNP#M 56 Perceiva 56 exome capture 56 AGS PSCA 56 lomitapide 56 CRMD# 56 drug PTK ZK 56 Trofex TM 56 VANTAS ® 56 neuropathy sparing 56 HuCNS SC ® 56 lymphoma leukemia 56 RhuDex TM 56 visceral metastases 56 MT#/MEDI-# 56 ABSORB trial 56 histologically confirmed 56 Optiquel ™ 56 hereditary medullary thyroid 56 Medullary thyroid cancer 56 familial hypercholesterolemia FH 56 dependent kinase inhibitor 56 OncoVEX 56 HyperAcute 56 lung esophageal 56 Lymphocytic 56 Lymphoseek ® 56 Gentamicin Surgical Implant 56 pelvic malignancies 56 visit www.rtanswers.org 56 CYP#A# CYP#D# 56 phase IIb clinical 56 LEAPS TM 56 Oral NKTR 56 Allovectin 7 ® 56 OMP #M# 56 JAK#/JAK# inhibitor CYT# 56 photodisinfection 56 Oral Calcitonin 56 cMET 56 BENLYSTA TM 56 oral renin inhibitor 56 Cand5 56 Phase 2b Clinical Trial 56 Artificial pancreas 56 delipidation 56 Phase III Pivotal 56 Apolipoprotein B 56 colorectal cancer liver metastases 56 Second Pivotal Phase 56 Tyrima 56 Acute leukemia 56 Pruvel 56 NU# direct 56 develop HBV reactivation 56 ToGA 56 Aurora Kinase 56 Alimentary Tract 56 genetics immunology 56 PEARL SC 56 colorectal gastric 56 refractory acute myeloid 56 gallium nitrate 56 extraction SPE 56 Phase III multicenter 56 topoisomerase II inhibitor 56 mouse xenograft models 56 CyPath ® diagnostic 56 intravenous RSD# 56 EHT AGN 56 psoriasis rheumatoid arthritis 56 MelaFind R 56 Prostate AdenoCarcinoma Treatment 56 MYTHOS trial 56 Vaxfectin TM formulated 56 FORTIS M trial 56 PDE# inhibitors 56 inflammatory autoimmune diseases 56 multifactorial disease 56 selectin antagonist 56 GAMMAGARD 56 Shows Promise Against 56 VALSTAR TM 56 malignant pancreatic 56 tosedostat 56 metastatic malignant melanoma 56 Phase #b/#a trial 56 midstage trials 56 atherosclerosis regression 56 radiation sensitizer 56 olaparib 56 advanced carcinoid 56 vaginally administered lidocaine 56 LE DT 56 Prognostic factors 56 Initiate Phase 56 Anthracycline 56 Inflammatory diseases 56 phase peptide synthesis 56 Exelixis XL# 56 Protexia ® 56 XP# XP# 56 imexon 56 ovarian cancer chronic hepatitis 56 sunitinib Sutent 56 REVIVE Diabetes 56 Glioblastoma Multiforme 56 proliferative retinopathy 56 novel emulsion formulation 56 orally administered inhibitor 56 elotuzumab 56 Cerebril TM 56 elacytarabine 56 investigational monoclonal antibody 56 CLIRS 56 induced oral mucositis 56 Thrombotic thromboembolic complications 56 genomic biomarker 56 multicenter randomized placebo controlled 56 AERx ® 56 thalidomide Thalomid 56 unresectable Stage III 56 Retreatment 56 Proxinium TM 56 myeloproliferative diseases 56 PHX# 56 Degarelix 56 NASH Huntington 56 psoriasis Crohn disease 56 castrate resistant 56 stage IIIb 56 Canvaxin 56 Biochip Array Technology 56 Diamyd ® 56 includes TOLAMBA TM 56 beta secretase inhibitors 56 haematological malignancies 56 PSN# [002] 56 RhuDex 55 modified glutathione analog 55 Aganocide 55 Vascular Disrupting Agent 55 opioid bowel dysfunction 55 Treatment Shows Promise 55 cathepsin K inhibitor 55 depsipeptide 55 treatment naïve genotype 55 hypoxia activated prodrug 55 OncoGel 55 BHT DNA 55 gastric pancreatic 55 epilepsy Parkinson disease 55 OncoVex 55 Kinoid 55 Genasense ® oblimersen 55 AEG# 55 Phase III ThermoDox 55 phase IIb trial 55 Daniel Junius 55 Symadex 55 neurology infectious 55 PS# DARA 55 cetuximab Erbitux 55 IND submission 55 opioid naive 55 TriGrid 55 axitinib 55 please visit www.advaxis.com 55 non squamous histology 55 AVOREN 55 recurrent glioblastoma multiforme 55 cancer neuroendocrine tumor 55 rheumatoid arthritis inflammatory bowel 55 molecular imaging radiopharmaceutical 55 EMPOWER ™ 55 Cloretazine 55 MYDICAR 55 placebo controlled dose escalation 55 Tocosol Paclitaxel 55 BACcelr8r TM 55 EndoTAG 55 metastatic HER2 negative 55 CR# vcMMAE 55 visit www.genenews.com 55 Zemiva TM 55 Phase III PREGNANT PROCHIEVE 55 stratifying patients